Anthony Paronneau advises clients on all aspects of corporate and business law, with a particular focus on pharmaceutical, medical device, biotech and health care industries.

Show More


  • Represented the shareholders of Anaconda Pharma, a French biotech, on its structured sale to the US group Biota Pharmaceuticals
  • Represented Arterial Remolding Technologies (ART), a French medtech developing an active bioabsorbable stent for the treatment of coronary disease, on its structured sale to the Japanese group Terumo Corporation
  • Advised the founders of Blink Biomedical SAS in the creation and first financing round of a new biotechnology company, formed by Valneva and the shareholders of Blink Therapeutics, and dedicated to the discovery of monoclonal antibodies

Show More


  • Legal 500 EMEA 2020, Healthcare & Life Sciences-France


HEC Paris School of Management, Graduate, DMI-04
Université Paris – Sud 11, DEA, Private Law, 2003
Université Paris – Sud 11, Maîtrise, Business Law, 2001


Show More

Anthony Paronneau

Insights & Events / Media

Paris, France / Speaking Engagements / April 4, 2018

San Francisco, California / McDermott Event / January 10, 2017